Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-084 in Refractory or Relapsed B-cell Precursor Acute Lymphoblastic Leukemia
NCT04601584Phase 2Terminated
- Sponsor
- Generium
- Start
- Oct 2020
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of GNR-084 in acute lymphoblastic leukemia (ALL), sponsored by Generium. Started Oct 2020; status: terminated.
02
Drugs
GNR-084
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04601584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601584.